Kindred Biosciences (KIN) Stock Price, News & Analysis

Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Key Stats

• Today's Range: $9.24 to $9.26
• 50-Day Range: $9.08 to $9.25
• 52-Week Range: $3.46 to $9.28
• Volume: 178,496 shs
• Average Volume: 840,890 shs
• Market Capitalization: $420.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Kindred Biosciences Stock Analysis - MarketRank™

Kindred Biosciences scored higher than 17% of companies evaluated by MarketBeat, and ranked 885th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Kindred Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kindred Biosciences are expected to grow in the coming year, from ($0.71) to ($0.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kindred Biosciences has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KIN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kindred Biosciences does not currently pay a dividend.

Dividend Growth

Kindred Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -1.96

Short Interest

There is no current short interest data available for KIN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for KIN on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kindred Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.69% of the stock of Kindred Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.89% of the stock of Kindred Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KIN Stock Analysis - Frequently Asked Questions

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 11/24/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KIN
• CUSIP: N/A
• CIK: 1561743
• Web: kindredbio.com
• Phone: (650) 701-7901
• Fax: N/A
• Employees: 63
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,800,000.00
• Net Margins: -529.26%
• Pretax Margin: N/A
• Return on Equity: -54.19%
• Return on Assets: -39.76%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 7.02
• Quick Ratio: 7.02

Sales & Book Value

• Annual Sales: $42.16 million
• Price / Sales: 9.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 45,462,000
• Free Float: N/A
• Market Cap: $420.52 million
• Optionable: Optionable
• Beta: 1.30